N-Glycolylneuraminic acid

N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) [1].

Product Specifications

CAS Number

[1113-83-3]

Product Name Alternative

NeuGc; GcNeu

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite; Influenza Virus

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/n-glycolylneuraminic-acid.html

Concentration

10mM

Purity

99.90

Solubility

H2O : 83.33 mg/mL (ultrasonic)

Smiles

O[C@@]1(O[C@H]([C@@H]([C@H](C1)O)NC(CO)=O)[C@@H]([C@@H](CO)O)O)C(O)=O

Molecular Formula

C11H19NO10

Molecular Weight

325.27

Precautions

H302, H315, H319, H335

References & Citations

[1]Takahashi T, et al. N-glycolylneuraminic acid on human epithelial cells prevents entry of influenza A viruses that possess N-glycolylneuraminic acid binding ability. J Virol. 2014 Aug;88 (15) :8445-56.|[2]Segatori VI, et al., Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160.